Fig. 3
Infiltration of ε-PCL implants by the tumor cells. a Proportion (%) of GFP + cells in the implants; the Gaussian distribution was used to model data from both nonenriched (μ = 17.45 ± 5.1, σ = 16 ± 8.6, R2≈46%) and VEGF enriched (μ = 0 ± 0.5, σ = 10.5 ± 1.6, R2≈94%) implants. This formed a negative linear trend between implants (η2 = 73.1%, ΔAIC = 7.98, ER = 53.96, p = 0.0237, Welch’s t test- *). b A relationship of inverse proportionality between mass of metastatic (GFP +) cells in the lungs and mass of tumor (GFP +) cells that infiltrated the nonenriched implant ( \(m\left(GFP+ cells\: in\: lungs\right)=b*{m\left(GFP+cells\: in\: the\: implant\right)}^{a}\), a = -0.34 ± 0.09, b = 144.711·103, 68% CI (30·103 to 462.063·103), R2 = 94%, ΔAIC = 11.6, ER≈330, p = 0.007-#). Legend: ε-PCL, eta polycaprolactone; μ, arithmetic mean; σ, standard deviation; m (GFP + cell in …), a mass of GFP + cells in lungs or the implant measured in mg; standard error is used as a measure of uncertainty of an estimate if the interval estimate is symmetric, if it is asymmetric the 68% confidence interval is used